Christine Garcia Roth, MD
Associate Professor of Pathology

Dr. Roth is the Co-Medical Director of the Clinical Flow Cytometry Laboratory and Director of the Hematopathology Core Residency Rotation.

Office Location:
Suite G300
UPMC-PUH
200 Lothrop Street
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-5191
Fax: 412-647-0374
Email: garciac@upmc.edu

Education

  • MD - Baylor College of Medicine, 2001
  • BA - Rice University , 1996

Certifications

  • Diplomate, American Board of Pathology, Anatomic and Clinical Pathology, 2006
  • Diplomate, American Board of Pathology, Specialty Certification in Hematology 2007
  • Diplomate, American Board of Pathology, Recertification in AP/CP/Hematology 2014

Specialties

Hematopathology

Clinical Expertise

Hematopathology, including bone marrow and lymph node pathology, and application of flow cytometric, immunohistochemical, cytogenetic, and molecular studies in clinical diagnosis

Research Expertise

Pathobiology and classification of hematopoietic processes, including myeloid and lymphoid malignancies, and applications of virtual simulation and microscopy to hematopathology education

Awards and Honors

  • Nominee, Resident Teaching Award in Clinical Pathology 2014,2012
  • Who's Who in America 2015 (69th Edition) 2014, 2015
  • Provost's Advisory Council on Instructional
  • Excellence (ACIE) Innovation in Education Award 2012

Selected Publications

View Dr. Roth's publications on PubMed

  1. Berg A, Soma L, Clark BZ, Swerdlow SH, Roth CG. Evaluating breast lymphoplasmacytic infiltrates: a multiparameter immunohistochemical study, including assessment of IgG4. Human Pathology 2015 Apr 28 [Epub ahead of print]
  2. Hellman C, Marcogliese AN, Djokic M, Roth CG. CD123 immunohistochemical expression is a specific but insensitive marker of early T-precursor leukemia. Applied Immunohistochemistry and Molecular Morphology 2015 Apr 21 [Epub ahead of print]
  3. Craig FE, McGee JB, Mahoney JF, Roth CG. The Virtual Pathology Instructor (V-PIN): A medical student teaching tool developed using patient simulator software." Human Pathology. 2014: 45(10) 1985 - 94.
  4. Garner K, Ten Eyck S, Craig FE, Roth CG. TIM3 is underexpressed on myeloblasts in untreated myelodysplastic syndrome. Leukemia Lymphoma. 2014; 55(3) 689-91.
  5. Chen ZW, Kotsikogianni I, Raval J, Roth C, Rollins-Raval MA. Biclonal IgD and IgM Plasma Cell Myeloma: Report of two cases and review of the literature" Case Reports in Hematology 2013: 293150 [Epub Nov 18]
  6. Roth CG, Garner K, Ten Eyck S, Boyiadzis M, Kane LP, Craig FE. TIM3 expression on normal and leukemic myeloblasts. Cytometry B Clin Cytom 2013; 84(3):167-72.
  7. Courville E, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Modern Pathology 2013; 26(6): 751-61.
  8. Rollins-Raval MA, Marafioti T, Swerdlow SH, Roth CG. The number and growth pattern of plasmacytoid dendritic cells vary in different types of reactive lymph nodes: an immunohistochemical study. Human Pathology. 2013; 44(6): 1003-10.
  9. Rollins-Raval MA, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Djokic M, Kant JA, Roth CG. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Applied Immunohistochemistry and Molecular Morphology. 2013; 21(3): 212-7.
  10. Roth CG, Reichard KK. Subtle bone marrow involvement by large B cell lymphoma with pronormoblast-like morphology and prominent but not exclusive sinusoidal distribution. American Journal of Blood Research. 2012; 2(2): 113-8.
  11. Roth CG, Dangott BJ, Harper T, Duboy J, Craig FE, Parwani A. Construction and implementation of a comprehensive hematopathology virtual teaching set. Journal of Hematopathology. 2012; 5(4) 297-304.
  12. Rollins-Raval MA, Roth CG. The value of CD14, CD123, CD33, MPO, and CD68R immunohistochemical stains in the diagnosis of acute and chronic myelomonocytic leukaemias. Histopathology. 2012; 60(6): 933-42.
  13. Rollins-Raval MA, Fuhrer K, Marafioti T, Roth CG. ALDH, Carbonic anhydrase 1, and CD2AP: Novel, diagnostically useful immunohistochemical markers to identify erythroid precursors in bone marrow biopsies. American Journal of Clinical Pathology. 2012; 137(1) 30-8.
  14. Rollins-Raval MA, Felgar F, Krasinskas AM, Roth CG. Significantly increased IgG4/IgG ratios may be rarely seen in lymph nodes of patients without IgG4-related sclerosing disease. International Journal of Surgical Pathology. 2012; 20(1): 47-53.
  15. Roth CG, Contis LC, Gupta S, Agha M, Safyan E. De novo acute myeloid leukemia with Philadelphia chromosome (BCR-ABL) and inversion 16 (CBFB-MYH11): Report of two cases and review of the literature. Leukemia Lymphoma 2011; 52 (3): 531 -5.
  16. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA. Acute erythroid leukemia: A reassessment using criteria refined in the 2008 WHO classification. Blood 2010; 115(10) 1985 - 92.
  17. Garcia CF, Hunt KE, Kang H, Babb A, Gale JM, Vasef MA, Reichard KK. Most morphologic features do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status. Appl Immun Molec Morph. 2010; 18(2): 119 - 27.
  18. Jankowitz RC, Gannon J, Blodgett TB, Garcia C, Jacobs S. A case of methotrexate-related lymphoproliferative disorder: clinical course and PET/CT findings. Case Reports in Medicine 2009 Volume 2009 Article ID 469343 [Epub]
  19. Garcia C, Gardner D, Reichard KK. CD163: A specific immunohistochemical marker for acute myeloid leukemia with monocytic differentiation. Appl Immun Molec Morph. 2008; 16(5): 417 - 21.
  20. Zembowicz A, Garcia CF, Tannous ZS, Mihm MC, Koerner F, Pilch BZ. Endocrine mucin-producing sweat-gland carcinoma: twelve new cases suggest that it is a precursor of some invasive mucinous carcinomas. Am J Surg Path 2005; 29: 1330 - 9.
  21. Tung RH, Garcia C, Morss AM, Pine RM, Pifer MA, Thompson BT, Lewandrowski K, Lee-Lewandrowski E, Januzzi JL. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Critical Care Medicine 2004; 32: 1643-7.